“If these results are replicated in Alzheimer’s disease patients, it would open up a promising avenue of treatment of this devastating neurodegenerative disease.”
Buphenyl, an FDA-approved medication for hyperammonemia, may protect memory and prevent the progression of Alzheimer’s disease. Hyperammonemia is a life-threatening condition that can affect patients at any age. It is caused by abnormal, high levels of ammonia in the blood.
Studies in mice with Alzheimer’s disease (AD) have shown that sodium phenylbutyrate, known as Buphenyl, successfully increases factors for neuronal growth and protects learning and memory, according to neurological researchers at the Rush University Medical Center.
Results from the National Institutes of Health funded study, recently were published in the Journal of Biological Chemistry.
“Understanding how the disease works is important to developing effective drugs that protect the brain and stop the progression of Alzheimer’s disease,” said Kalipada Pahan, PhD, the Floyd A. Davis professor of neurology at Rush and lead investigator of this study.
A family of proteins known as neurotrophic factors help in survival and function of neurons. Past research indicates that these proteins are drastically decreased in the brain of patients with Alzheimer’s disease (AD).
“Neurotrophic factor proteins could be increased in the brain by direct injection or gene delivery,” said Pahan. “However, using an oral medication to increase the level of these protein may be the best clinical option and a cost effective way to increase the level of these proteins directly in the brain.”
“Our study found that after oral feeding, Buphenyl enters into the brain, increases these beneficial proteins in the brain, protects neurons, and improves memory and learning in mice with AD-like pathology,” said Pahan.
In the brain of a patient with AD, two abnormal structures called plaques and tangles are prime suspects in damaging and killing nerve cells. While neurons die, other brain cells like astroglia do not die.
The study findings indicate that Buphenyl increases neurotrophic factors from astroglia. Buphenyl stimulates memory-related protein CREB (cyclic AMP response element-binding protein) using another protein known as Protein Kinase C (PKC) and increases neurotrophic factors in the brain.
“Now we need to translate this finding to the clinic and test Buphenyl in Alzheimer’s disease patients,” said Pahan. “If these results are replicated in Alzheimer’s disease patients, it would open up a promising avenue of treatment of this devastating neurodegenerative disease.”
The Latest Bing News on:
Alzheimer’s
- Alzheimer’s doesn’t cloud Michigan woman’s love for opera singingon April 27, 2024 at 7:00 am
She performed through the 1980s at venues like the Seattle Opera, Carnegie Hall and the Metropolitan Opera House and has a lengthy list of awards and accolades over the years.
- Neuroscientists Warn of 'Cascading' Alzheimer's Risk From These Two Habitson April 27, 2024 at 6:59 am
The habits produce a "synergistic effect" on our risk of developing Alzheimer's Disease and general cognitive decline.
- Challenging Old Theories: Innovative Microscopy Exposes New Alzheimer’s Treatment Pathwayson April 27, 2024 at 3:35 am
Researchers at UC San Diego have utilized advanced imaging techniques to explore the metabolic processes behind Alzheimer's disease, leading to potential new strategies for treatment. Alzheimer's ...
- Commentary: As Alzheimer’s risk grows, caregivers need supporton April 27, 2024 at 2:30 am
According to a new report from the Florida Chapters of the Alzheimer’s Association, an estimated one in eight people are living with Alzheimer’s. More than 840,000 are serving as their unpaid ...
- Study says these three diets reduce Alzheimer's diseaseon April 26, 2024 at 1:48 pm
New research showed people's diet and other activities that challenge the brain may help fight off Alzheimer's disease.
- Alzheimer's All-Star Basketball Classic's founder, Gordon Thomas, inspired by dad's battle with diseaseon April 26, 2024 at 11:50 am
Celeste Taylor, Lester Quinones and Diego Maldonado are just a few of the talented players who have participated in the competitions.
- AI helps researchers uncover gut-brain interactions in Alzheimer'son April 26, 2024 at 10:00 am
AI technology reveals more information about the gut-brain health link in Alzheimer's, suggesting new pathways for research around treatments.
- For Beaten-Down Maker of Alzheimer’s Drug, Good Enough Will Doon April 25, 2024 at 8:00 am
In-line sales for Alzheimer’s drug Leqembi and a beat for rare-disease drug Skyclarys has Wall Street giving Biogen another chance.
- Florida clinic plans to treat 10,000 Alzheimer’s patients a year. Look at what’s comingon April 25, 2024 at 7:20 am
Roskamp’s planned Bishop-Parker Clinic will enable Roskamp to assess, treat and support more than 10,000 patients a year, Wendy Deming, CEO of the Bishop-Parker Foundation, said Wednesday.
- Aggressive Alzheimer's patients don't have to suffer under Medicaidon April 25, 2024 at 2:10 am
Centers for Medicare and Medicaid Services do not allow chemical restraints like sedation in any state for obvious reasons. Indiana is no exception. Aggressive individuals cannot be kept in a ...
The Latest Google Headlines on:
Alzheimer’s
[google_news title=”” keyword=”Alzheimer’s” num_posts=”10″ blurb_length=”0″ show_thumb=”left”] [/vc_column_text]The Latest Bing News on:
Buphenyl
- Buphenyl Powderon February 14, 2012 at 12:42 pm
Sodium phenylbutyrate 940mg/gram; contains sodium 11.7g/100g of pwd. Adjunct in the chronic management of urea cycle disorders involving deficiencies of carbamylphosphate synthetase, ornithine ...
The Latest Google Headlines on:
Buphenyl
[google_news title=”” keyword=”Buphenyl” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]